CMX-020 is effective in treating osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, fibromyalgia, and sciatica indications. Cmxtwenty has completed Phase 1 studies with both oral and intravenous products and has initiated Phase 2 POC studies with oral CMX-020 in patients with sciatica in Adelaide, Australia. An oral version of CMX-020 provides efficacy through 6-8 hours in human studies, while intravenous administration is uniquely suited for controlling varying levels of pain in a hospital setting.